Biocryst Pharmaceuticals INC

BioCryst Pharmaceuticals provides updated cost estimates for its plan to discontinue internal discovery programs and close its Birmingham facility.

BioCryst Pharmaceuticals announced a strategic shift to discontinue internal discovery programs and close its Birmingham, Alabama facility by year-end 2026, focusing on external innovation and reaffirming revenue guidance while lowering operating expense projections.

BioCryst Pharmaceuticals stockholders approved an amendment to the company's Stock Incentive Plan, authorizing an additional 7,000,000 shares for issuance.

BioCryst Pharmaceuticals announced first quarter 2026 financial results, highlighting strong ORLADEYO revenue growth and a significant licensing agreement for navenibart in Europe.

BioCryst Pharmaceuticals has entered into a licensing agreement with an Irish affiliate of Neopharmed Gentili S.p.A. for the commercialization of navenibart in Europe, securing $70 million upfront and potential future payments.

BioCryst Pharmaceuticals reported record full-year 2025 financial results, achieving profitability for the first time, driven by strong ORLADEYO sales and strategic business developments.

BioCryst Pharmaceuticals achieved net income and positive operating cash flow in Q3 2025, driven by strong ORLADEYO sales, and announced a strategic merger with Astria Therapeutics.

BioCryst Pharmaceuticals reports significant revenue growth and net income for the first half of 2025, driven by strong ORLADEYO sales and strategic debt reduction.

BioCryst reports a strong first quarter in 2025, driven by increased ORLADEYO sales and progress in its clinical development programs.

BioCryst Pharmaceuticals saw a significant increase in revenue in Q3 2024, primarily driven by sales of its hereditary angioedema drug, ORLADEYO, despite ongoing losses.

BioCryst Pharmaceuticals saw a revenue increase in Q2 2024, driven by ORLADEYO sales, but still reported a net loss due to high operating expenses and interest costs.

BioCryst Pharmaceuticals saw a revenue increase in the first quarter of 2024, primarily driven by sales of Orladeyo, despite ongoing operating losses.

BioCryst Pharmaceuticals achieved significant revenue growth and profitability in 2025, driven by ORLADEYO sales and strategic acquisitions, while expanding its rare disease pipeline.

BioCryst Pharmaceuticals reports strong ORLADEYO sales growth and pipeline progress in its 2024 10-K filing, highlighting its focus on rare diseases and profitability.

BioCryst Pharmaceuticals' 2023 annual report details financial performance and advancements in its rare disease drug pipeline, including ORLADEYO and BCX10013.

BioCryst Pharmaceuticals reports a stock grant and option award to Director Jill C. Milne.

Steven K. Galson, a Director at BioCryst Pharmaceuticals, Inc., received a grant of Restricted Stock Units and stock options.

Director Alan G. Levin of BioCryst Pharmaceuticals received a grant of restricted stock units and stock options, as disclosed in a Form 4 filing.

Director Frank Steven of BioCryst Pharmaceuticals received a grant of restricted stock units and stock options as part of the company's non-employee director compensation policy.

BioCryst Pharmaceuticals reports a stock grant and option award to Director Machelle Sanders.

BioCryst Pharmaceuticals reports a stock grant and option award to Director Vincent Milano, reflecting compensation and alignment with company performance.

BioCryst Pharmaceuticals, Inc. has issued its proxy statement for the Annual Meeting of Stockholders scheduled for June 11, 2026, detailing proposals for director elections, auditor ratification, executive compensation, and stock incentive plan amendments.

BioCryst Pharmaceuticals announces its 2025 Annual Meeting of Stockholders, detailing proposals including director elections, auditor ratification, executive compensation vote, and stock incentive plan approval.

BioCryst Pharmaceuticals is asking stockholders to approve an amended stock incentive plan to increase the number of shares available for issuance at the annual meeting on June 12, 2025.

BioCryst Pharmaceuticals has filed a definitive proxy statement with the SEC.

BioCryst Pharmaceuticals is asking stockholders to approve an amended and restated Stock Incentive Plan, increasing the number of shares available for issuance by 7,000,000.

State Street Corporation has filed a Schedule 13G, reporting beneficial ownership of 4.9% of BioCryst Pharmaceuticals Inc. common stock as of March 31, 2026.

Vanguard Capital Management has disclosed a beneficial ownership of 5.16% of BioCryst Pharmaceuticals' common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in BioCryst Pharmaceuticals Inc. following an internal realignment.

Deerfield Mgmt, L.P. and its affiliates have reported a 6.81% beneficial ownership stake in BioCryst Pharmaceuticals, Inc. common stock.

State Street Corporation has reported a 5.3% beneficial ownership stake in BioCryst Pharmaceuticals Inc. common stock as of December 31, 2025.

RA Capital Management and its affiliates have reported a 7.3% passive ownership stake in BioCryst Pharmaceuticals, Inc., holding over 15 million shares.